Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics

Article Sidebar

pdf
Published: Oct 13, 2022
Keywords:
Gluconeogenesis,, imeglimin, oxidative, phosphorylation, inhibitor,, mitochondria, pharmacotherapeutics, type 2 diabetes mellitus

Main Article Content

Dr Sanjay Kalra
Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India
Dr Saptarshi Bhattacharya
Dept. of Endocrinology, Apollo Indraprastha Hospital, New Delhi, India
Dr Shehla Shaikh
Dept. of Endocrinology, Saifee Hospital, Mumbai, Maharashtra, India

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.

Article Details

How to Cite
Dr Sanjay Kalra, Dr Saptarshi Bhattacharya, & Dr Shehla Shaikh. (2022). Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics. Indian Journal Of Clinical Practice, 33(5), 8–10. Retrieved from https://ojs.ijcp.in/IJCP/article/view/305
Issue
Vol. 33 No. 5 (2022)
Section
Guest Editorial

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>